rsv604
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2005 (NCT00232635)
Timeline
Indications
Mechanism of action
- Respiratory syncytial virusINHIBITOR
Respiratory syncytial virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 1-(2-fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1h-benzo(e)(1,4)diazepin-3-yl)urea
- a-60444
- a-60444
- rsv604
- rsv604
- rsv604
- rsv 604
- rsv-604
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00416442 | Phase 1 | Oct 1, 2006 | Novartis |
| NCT00232635 | Phase 2 | Sep 1, 2005 | Arrow Therapeutics, University of London |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arrow Therapeutics | For profit | 1 | 1 | 1 | 2005 |
| Novartis | For profit | 1 | 1 | 1 | 2006 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2005 |
3 organizations
Page 1 / 1